Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2017

Open Access 01-12-2017 | Research article

What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review

Authors: Sverre Georg Sæther, Morten Schou, Daniel Kondziella

Published in: BMC Psychiatry | Issue 1/2017

Login to get access

Abstract

Background

Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric symptoms in patients with and without paraneoplastic central nervous system syndromes.

Methods

Eligible studies were selected from 1980 until February 2017 according to standardized review criteria and evaluated using Quality Assessment of Diagnostic Accuracy Studies−2 (QUADAS-2). We included studies describing the psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in patients with psychiatric disorders.

Results

Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized onconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in controls was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychotic and depressive syndromes, respectively.

Conclusions

The available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.
Appendix
Available only for authorised users
Literature
1.
2.
Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain : a journal of neurology. 2000;123(Pt 7):1481–94.CrossRef
3.
Zhang H, Zhou C, Wu L, Ni F, Zhu J, Jin T. Are onconeural antibodies a clinical phenomenology in paraneoplastic limbic encephalitis? Mediat Inflamm. 2013;2013:172986.
4.
Bosemani T, Huisman TA, Poretti A. Anti-Ma2-associated paraneoplastic encephalitis in a male adolescent with mediastinal seminoma. Pediatr Neurol. 2014;50(4):433–4.CrossRefPubMed
5.
Didelot A, Honnorat J. Paraneoplastic disorders of the central and peripheral nervous systems. Handb Clin Neurol. 2014;121:1159–79.CrossRefPubMed
6.
Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA. Onconeural antibodies in sera from patients with various types of tumours. Cancer immunology, immunotherapy: CII. 2009;58(11):1795–800.CrossRefPubMed
7.
Stich O, Rauer S. Paraneoplastic neurological syndromes and autoimmune encephalitis. Nervenarzt. 2014;85(4):485–98. quiz 99-501CrossRefPubMed
8.
Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–40.CrossRefPubMedPubMedCentral
9.
Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology. 1998;51(4):1146–50.CrossRefPubMed
10.
Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999;45(2):162–7.CrossRefPubMed
11.
Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol. 2014;128(6):835–52.CrossRefPubMedPubMedCentral
12.
Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol. 2010;69(10):997–1007.CrossRefPubMedPubMedCentral
13.
Greenlee JE, Clawson SA, Hill KE, Wood B, Clardy SL, Tsunoda I, et al. Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. J Neuroinflammation. 2014;11:160.CrossRefPubMedPubMedCentral
14.
Greenlee JE, Clawson SA, Hill KE, Wood B, Clardy SL, Tsunoda I, et al. Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers. PLoS One. 2015;10(4):e0123446.CrossRefPubMedPubMedCentral
15.
Kayser MS, Kohler CG, Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry. 2010;167(9):1039–50.CrossRefPubMed
16.
Endres D, Perlov E, Stich O, Meyer PT, Lutzen N, Tebartz van Elst L. Case report: low-titre anti-Yo reactivity in a female patient with psychotic syndrome and frontoparieto-cerebellar atrophy. BMC psychiatry. 2015;15:112.CrossRefPubMedPubMedCentral
17.
Laadhar L, Sidhom O, Zitouni M, Sassi N, Abdelghaffar W, Lahmar H, et al. High prevalence of antineuronal antibodies in Tunisian psychiatric inpatients. The Journal of neuropsychiatry and clinical neurosciences. 2015;27(1):54–8.CrossRefPubMed
18.
Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC medical informatics and decision making. 2007;7:16.CrossRefPubMedPubMedCentral
19.
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.CrossRefPubMed
20.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009;339:b2700.CrossRef
21.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
22.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (3rd edition, revised). American Psychiatric Association. 1987.
23.
American Psychiatric Association. Diagnostic and statistical manual for mental disorders (4th edition). American Psychiatric Association. 1994.
24.
25.
Hammack JE, Kimmel DW, O'Neill BP, Lennon VA. Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies. Mayo Clin Proc. 1990;65(11):1423–31.CrossRefPubMed
26.
Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine. 1992;71(2):59–72.CrossRefPubMed
27.
Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42(10):1931–7.CrossRefPubMed
28.
Alamowitch S, Graus F, Uchuya M, Rene R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain : a journal of neurology. 1997;120(Pt 6):923–8.CrossRef
29.
Black JL, Lamke GT, Walikonis JE. Serologic survey of adult patients with obsessive-compulsive disorder for neuron-specific and other autoantibodies. Psychiatry Res. 1998;81(3):371–80.CrossRefPubMed
30.
Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol. 1999;56(2):172–7.CrossRefPubMed
31.
Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999;340(23):1788–95.CrossRefPubMed
32.
Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146–54.CrossRefPubMed
33.
Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002;249(6):745–53.CrossRefPubMed
34.
Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc. 2003;78(11):1363–8.CrossRefPubMed
35.
Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain : a journal of neurology. 2004;127(Pt 8):1831–44.CrossRef
36.
Overeem S, Dalmau J, Bataller L, Nishino S, Mignot E, Verschuuren J, et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology. 2004;62(1):138–40.CrossRefPubMedPubMedCentral
37.
Hoffmann LA, Jarius S, Pellkofer HL, Schueller M, Krumbholz M, Koenig F, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry. 2008;79(7):767–73.CrossRefPubMed
38.
McKeon A, Tracy JA, Pittock SJ, Parisi JE, Klein CJ, Lennon VA. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol. 2011;68(10):1282–9.CrossRefPubMed
39.
Chiaie RD, Caronti B, Macri F, Campi S, Marino M, Corrado A, et al. Anti-purkinje cell and natural autoantibodies in a group of psychiatric patients. Evidences for a correlation with the psychopathological status. Clinical practice and epidemiology in mental health : CP & EMH. 2012;8:81–90.CrossRef
40.
Saraya A, Mahavihakanont A, Shuangshoti S, Sittidetboripat N, Deesudchit T, Callahan M, et al. Autoimmune causes of encephalitis syndrome in Thailand: prospective study of 103 patients. BMC Neurol. 2013;13:150.CrossRefPubMedPubMedCentral
41.
Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014;76(1):82–94.CrossRefPubMed
42.
Endres D, Perlov E, Baumgartner A, Hottenrott T, Dersch R, Stich O, et al. Immunological findings in psychotic syndromes: a tertiary care hospital's CSF sample of 180 patients. Front Hum Neurosci. 2015;9:476.CrossRefPubMedPubMedCentral
43.
Haukanes BI, Hegvik TA, Eichler T, Haavik J, Vedeler C. Paraneoplastic syndrome-associated neuronal antibodies in adult ADHD. J Neuroimmunol. 2015;288:87–91.CrossRefPubMed
44.
Kruse JL, Lapid MI, Lennon VA, Klein CJ, Toole OO, Pittock SJ, et al. Psychiatric Autoimmunity: N-Methyl-D-Aspartate Receptor IgG and Beyond. Psychosomatics. 2015;56(3):227–41.CrossRefPubMed
45.
Endres D, Perlov E, Dersch R, Baumgartner A, Hottenrott T, Berger B, et al. Evidence of cerebrospinal fluid abnormalities in patients with depressive syndromes. J Affect Disord. 2016;198:178–84.CrossRefPubMed
46.
47.
Moon J, Lee ST, Shin JW, Byun JI, Lim JA, Shin YW, et al. Non-stiff anti-amphiphysin syndrome: clinical manifestations and outcome after immunotherapy. J Neuroimmunol. 2014;274(1–2):209–14.CrossRefPubMed
48.
Hansen N, Widman G, Witt JA, Wagner J, Becker AJ, Elger CE, et al. Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis. Epilepsy & behavior : E&B. 2016;65:18–24.CrossRef
49.
Schwenkenbecher P, Chacko LP, Wurster U, Pars K, Pul R, Suhs KW, et al. Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis. BMC Neurol. 2016;16(1):136.CrossRefPubMedPubMedCentral
Metadata
Title
What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review
Authors
Sverre Georg Sæther
Morten Schou
Daniel Kondziella
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2017
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-017-1325-z

Other articles of this Issue 1/2017

BMC Psychiatry 1/2017 Go to the issue

Study protocol

The PULSAR Specialist Care protocol: a stepped-wedge cluster randomized control trial of a training intervention for community mental health teams in recovery-oriented practice

Research article

Characteristics of cardio-Cerebrovascular modulation in patients with generalized anxiety disorder: an observational study

Research article

The Japanese version of the questionnaire about the process of recovery: development and validity and reliability testing

Research article

Effect of short-term heart rate variability biofeedback on long-term abstinence in alcohol dependent patients – a one-year follow-up

Research article

Implementation of early intensive behavioural intervention for children with autism in Switzerland

Research article

Retinoids, anxiety and peripartum depressive symptoms among Chinese women: a prospective cohort study